Review the structure, function, and role of CMYC gene in tumorigenesis
MYC
(MYC proto-oncogene, bHLH transcription factor) Hybridization with Vysis LSI MYC break apart and LSY MYC probe (Abbott Molecular, US) showing the gene on 8q24.21 -Courtesy Adriana Zamecnikova.
Note
MYC gene encodes a multifunctional, nuclear phosphoprotein that controls a variety of cellular functions, including cell cycle, cell growth, apoptosis, cellular metabolism and biosynthesis, adhesion, and mitochondrial biogenesis. MYC has been shown to be an essential global transcription factor capable of either promoting or repressing the expression of a massive array of genes, accounting for >15% of the human genome, commonly referred to as the "MYC signature" (Knoepfler 2007) . MYC is among the most frequently affected gene in human cancers, overexpressed in most human cancers and contributes to the cause of at least 40% of tumors. Dysregulation of MYC expression results through various types of genetic alterations leading to a constitutive activity of MYC in various cancers (Dang et al, 2006) .
DNA/RNA
Description CMYC is composed of three exons spanning over 4 kb with the second and third exons encoding most MYC protein. These two exons have at least 70% sequence homology among species. However, exon1 is untranslated whose sequence is not as well conserved through evolution. The exon1 has been postulated to play a role in translational control and mRNA stability.
There are four MYC transcriptional promoters. In normal cells, promoter P2 contributes to approximately 75% of total MYC transcripts while P1 accounts for most the remaining 25% transcripts (Dang CV 2012) .
Transcription
MYC mRNA contains an IRES (internal ribosome entry site) that allows the RNA to be translated into protein when 5' cap-dependent translation is inhibited, such as during viral infection.
Protein
Description 439 amino acids and 48 kDa in the p64; 454 amino acids in the p67 (15 additional amino acids in Nterm; contains from N-term to C-term: a transactivation domain, an acidic domain, a nuclear localization signal, a basic domain, an helix-loophelix motif, and a leucin zipper; DNA binding protein.
Expression
Expressed in almost all proliferating cells in embryonic and adult tissues; in adult tissues, expression correlates with cell proliferation; abnormally high expression is found in a wide variety of human cancers.
Localisation
located predominantly in the nucleus.
The myc protein contains an unstructured N-terminal transcriptional regulatory domain followed by a nuclear localization signal and a C-terminal region with a basic DNA-binding domain tied to a helixloop-helix-leucine zipper (bHLHZip) dimerization motif. The bHLHzip motif of MYC dimerizes with the MAX, which is a prerequisite for specific binding to DNA at E-box sequences (5'-CA(C/T)G(T/C)G-3') (Dang 2012) . Upon DNA binding the MYC/MAX heterodimer recruits cofactors, which mediate multiple effects of MYC on gene expression in a context-dependent manner. This dimerization process is essential for induction of cell cycle progression, apoptosis, and transformation suggesting that MYC exerts its oncogenic effects by transactivation of target genes via E-boxes (Amati B, Land H, 1994; Grandori C et al 2000) . The coding exons of MYC encode for the N-terminal region which has a transcriptional regulatory domain, a region that contains conserved MYC Boxes I and II, followed by MYC Box III and IV, and a nuclear targeting sequence. The N-terminal region will bind with co-activator complexes, making MYC acts as the transcription or repression factor (Cowling et al 2006) . (Amati and Land, 1994) . MXI1 protein is also regulated. MYC-MAX heterodimers activate transcription through interactions with transcriptional coactivators ( TRRAP, ACTL6A (BAF53)) and their associated histone acetyltransferases and/or ATPase/helicases, resulting in transition from the G0/1 phase to the S phase (Nilsson and Cleveland, 2003) . Several studies have established that MAX is essential for MYCmediated gene transactivation, transformation, cell cycle progression and apoptosis. On the other hand, overexpression of MXI1 and MXD1 can antagonize MYC activity in cellular transformation assays and proliferation and can diminish the malignant phenotype of tumor cells. MXD1 can also inhibit apoptosis and reverse the differentiation blocking effect of MYC in leukemia cells. (Dang 2012) . These findings are consistent with the concept that MXD1 and MXI1 suppress MYC function. In addition to interacting with proteins involved in transcription regulation, MYC also interacts with enzymes controlling histone methylation.
Target Genes Thousands of MYC target genes have been identified by following mRNA levels in experimentally controlled activation of the MYC gene (Menssen and Hermeking 2002) . In general, genes targeted by MYC include mediators of metabolism, biosynthesis, and cell cycle progression, such that aberrant MYC expression is associated with uncontrolled cell growth, division, and metastasis, whereas loss or inhibition of MYC expression hinders growth, promotes differentiation, and sensitizes cells to DNA damage (Miller 2012; Hsieh 2015) . Different target genes are regulated under specific conditions for specific cell types. Some of the most biologically important targets are CCND2 (cyclin D2), and cyclin-dependent kinases (CDKs), resulting in accelerated cell cycling; downregulation of PTEN (phosphatase and tensin homolog deleted on chromosome ten) with consequent up-regulation of the phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/ MTOR) pathway; and stabilization of the proapoptotic protein and tumor suppressor TP53, (Hoffman and Liebermann 2008; Dang 2012 ) which can bypass the apoptotic BCL2 program. MYC, on the other hand, activates many ribosomal protein genes including RPL23, which binds to and retains NPM1 in the nucleolus, thereby inhibiting PIAS2 (Miz-1) activity (Wanzel, 2008) . MYC itself is modulated by NPM1, which acts as a positive MYC coactivator (Schneider A 1997; Grandori C et al., 2005; Li Z, et al 2008) .
MYC-targeted gene network also contains nonprotein coding targets; among those are microRNAs (miRNAs). The miRNAs are 18-22 nucleotides noncoding RNAs that negatively regulate gene expression at the post-transcriptional level via binding to 3'-UTRs of target mRNAs and mediate translational repression or mRNA degradation. Some miRNA function as an oncogene while others behave as tumor suppressor gene, in a cell-typed manner. Growing evidences have suggested that MYC regulates the expression of a number of miRNAs, resulting in widespread repression of miRNA and, at the same time, MYC being subjected to regulation by miRNAs, leading to sustained MYC activity and the corresponding MYC downstream pathways (Chang et al, 2008 Another MYCinduced miRNA, MIR22, was recently shown to act as a potent proto-oncogenic miRNA by genomewide deregulation of the epigenetic state through inhibition of methylcytosine dioxygenase TET proteins. In addition, MIR22 was characterized as a key regulator of self-renewal in the hematopoietic system. MYC also represses several miRNAs with tumor suppressor function such as MIR15A/ MIR16-1 and miR-34 that regulate apoptosis by targeting BCL2 and TP53 respectively. Likewise MYC is negatively regulated by several miRNAs such as miR-34 and MIR494. The auto functional interaction between MYC and miRNAs target genes maintains persistent expression of MYC, thus promoting the malignant phenotype (Tao et al 2014; Jackstadt 2015) .
Furthermore, over expression of MYC can induce apoptosis. The apoptosis triggered or sensitized by MYC can be either TP53-dependent or TP53 independent, determined by the cell type and apoptotic trigger. The mechanisms of MYCmediated apoptosis may involve several pathways. Overexpression of MYC increases DNA replication and possibly results in DNA damage that, in turn, triggers a TP53-mediated response leading to apoptosis, in some cell types (Hoffman and Libermann, 2008) . As well, MYC expression seems to downregulate antiapoptotic proteins such as BCL2 or BCL2L1 (Bcl-XL) and upregulate pro-apoptotic elements such as BCL2L11 (BIM).
MYC also plays an important role in mitochondrial biogenesis. Large scale studies of gene expression in rat and human systems first suggested that MYC overexpression can induce nuclear encoded mitochondrial genes. In addition, MYC has been shown to bind to the promoters of genes encoding proteins involved in mitochondrial function. Using an inducible MYC-dependent human B cell model of cell proliferation it was shown that mitochondrial biogenesis is completely dependent on MYC expression. Moreover, the genes involved with mitochondrial biogenesis are among the MYC target genes most highly induced (Gao et al 2009) .
Implicated in

Top note
MYC Deregulation
The expression of MYC is deregulated in cancer by several different mechanisms, including chromosomal translocations, amplifications, point mutations, epigenetic reprogramming, enhanced translation and increased protein stability. In most cases these alterations lead to a constitutive expression of intact MYC protein, which is normally only expressed during certain phases of the cell cycle. In Burkitt lymphoma (BL), the MYC oncogene is activated through a reciprocal t(8;14) or its variant which juxtaposes MYC/8q24 to enhancer of the immunoglobulin (Ig) heavy Chain (IGH) locus on chromosome 14q32 or the kappa or lambda light chain locus on chromosome 2 or 22. There are three main translocation breakpoints in MYC; class I breakpoints are within the exon 1 and first intron of MYC; class II breakpoints are located at the 5' end of the MYC, and usually within a few kilobases of exon 1; and the class III breakpoints are distant from MYC itself, and can be more than 100 kb away. Endemic BL typically shows class II translocation breakpoints in MYC while the sporadic BL often exhibits class I breakpoints of MYC. The t(8;14) or its variant is considered as an initiative event in BL. The MYC/8q24 translocations may also occur as secondary events in non-BL lymphomas such as diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and multiple myeloma (Cai et al, 2015; Nguyen L, et al 2017) . Secondary MYC translocation is associated with a complex karyotype and most often confer aggressive clinical behavior and poor outcome. Recently, B-cell large cell lymphoma with MYC and BCL2 or/and BCL6 rearrangements so called double hit or triple hit lymphoma are recognized by the 2016 revision of WHO as a subset of a very aggressive lymphoma (Petrich 2014) . > Amplification of MYC gene has been shown in both hematopoietic and non-hematopoietic tumors, including lung, breast, colon, and prostate cancers. Insertional mutagenesis is seen in retrovirus-induced tumors, such as avian leucosis virus (ALV)-induced hematopoietic tumors, in which the proviral enhancer is integrated upstream of the MYC gene and leads to its overexpression. MYC overexpression may also occur because of posttranslational modifications. MYC protein overexpression as a result of point mutations in Nterminal domain is also frequent. The most recurrently mutated residue is Thr-58, found in lymphoma. Normally, the phosphorylation of Thr-58 can control MYC degradation and mutation causing increase of MYC protein half-life in lymphoma (Cai et al 2017) . Detection of MYC rearrangement is important in the diagnosis of BL and as a prognostic marker in other aggressive B-cell lymphomas. There are several techniques to detect MYC deregulation including conventional cytogenetics, fluorescence in situ hybridization (FISH), and immunohistochemistry. In clinical laboratory, FISH is being most frequently used approach (Figure 2 ) >
MYC as therapeutic target
MYC (MYC proto-oncogene, bHLH transcription factor)
MYC is documented to be involved broadly in many cancers, in which its expression is estimated to be elevated or deregulated in up to 70% of human cancers. Overexpression of MYC protein is not only to drive tumor initiation and progression, but is also essential for tumor maintenance. Furthermore, growth arrest, apoptosis and differentiation occur upon reduction in MYC levels. These features make MYC molecule a highly attractive target for cancer therapy. However, the lack of deep pocket in the structure of MYC protein makes the traditionally small molecule inhibitors are not feasible. For this reason, other alternative strategies are proposed. One approach suggests that the disruption of the MYC/MAX binding site can be a strategy for the inactivation of MYC function in neoplastic cells. Such an approach was already applied and different small molecule inhibitors that can specifically target MYC were already successfully produced. Other approach is based on the inhibition of MYC/MAX dimers binding to E-boxes in the promoters of different MYC target genes. Other groups have focused on transcriptional inhibition of the MYC gene. Preliminary evidence from experiments using MYC antisense oligonucleotides has been encouraging, but has not translated into effective clinical treatments ( Koh 2016 
Note
Breakpoints
